Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
-
Published:2023-10-10
Issue:6
Volume:12
Page:1959-1960
-
ISSN:2193-8253
-
Container-title:Neurology and Therapy
-
language:en
-
Short-container-title:Neurol Ther
Author:
Aldred JasonORCID,
Freire-Alvarez EricORCID,
Amelin Alexander V.ORCID,
Antonini AngeloORCID,
Bergmans BrunoORCID,
Bergquist FilipORCID,
Bouchard Manon,
Budur Kumar,
Carroll CamilleORCID,
Chaudhuri K. RayORCID,
Criswell Susan R.ORCID,
Danielsen Erik H.,
Gandor FlorinORCID,
Jia Jia,
Kimber Thomas E.ORCID,
Mochizuki HidekiORCID,
Robieson Weining Z.ORCID,
Spiegel Amy M.,
Standaert David G.ORCID,
Talapala Saritha,
Facheris Maurizio F.,
Fung Victor S. C.ORCID
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology